To assess the effects, we generated a pair of anti-PD-1 antibodies: BGB-A317/IgG4S228P and BGB-A317/IgG4-variant (abbreviated mainly because BGB-A317), with the same variable areas but two different IgG4 Fc-hinge sequences. to PD-1. However, BGB-A317/IgG4S228P binds to human being FcRI with high affinity and mediates crosslinking between PD-1 and FcRI. In contrast, BGB-A317 does neither. Further cell-based assays showed that such crosslinking could reverse the function of an anti-PD-1 antibody from obstructing to activating. More importantly, the crosslinking induces FcRI+ macrophages to phagocytose PD-1+ T cells. Inside a mouse model transplanted with allogeneic human being tumor cells and PBMCs, BGB-A317 showed significant tumor growth inhibition, whereas BGB-A317/IgG4S228P experienced no such inhibition. Immunohistochemistry study exposed an inverse correlation between FcRI+ murine macrophage infiltration and the denseness of CD8+PD-1+ human being T cells within tumors in the BGB-A317/IgG4S228P-treated group. These evidences suggested that FcRI+ binding and crosslinking experienced bad impact on the anti-PD-1 antibody-mediated anti-cancer activity. Electronic supplementary material The online version of this article (10.1007/s00262-018-2160-x) NK314 contains supplementary material, which is available to authorized users. Keywords: PD-1, Antibody, FcRI, Macrophages, Malignancy therapy Introduction Defense surveillance plays a critical role in malignancy prevention. However, in situations where tumors develop resistance mechanisms to suppress the sponsor immune system, tumors eventually grow out of control [1, 2]. One NK314 of such resistance mechanism is the up-regulation of the immune check-point ligand, PD-L1, in tumor cells or in tumor-associated immune cells. PD-L1 interacts with PD-1 (programmed cell death-1) on T cells, inhibiting T-cell proliferation and effector functions such as cytokine secretion and tumor cell-killing [3, 4]. Several PD-1 antagonist antibodies have been tested in medical trials, and display significant effectiveness in the treatment of advanced malignancy types [5C9]. Two anti-PD-1 antibodies, nivolumab, and pembrolizumab recently gained regulatory authorization [3]. Antibody medicines exert main pharmacodynamic effects through specific binding to a target protein and modulating its practical activity via the variable areas. Furthermore, the constant region of an antibody also takes on important tasks by exerting secondary pharmacodynamic effects through the binding to FcRs or activation of match cascade. Each IgG subclass has a unique set of features for binding to effector receptors that elicit serious functional effects on the prospective cells [10, 11]. Most of the anti-PD-1 monoclonal antibodies (mAb), including nivolumab and pembrolizumab, have IgG4S228P weighty chain, which retains effector-binding functions similar to that of wild-type human being IgG4 [11], while it possesses more stable dimeric structure without fab-arm exchange observed in wild-type IgG4 [12, 13]. It was well recorded that human being IgG4 offers significant binding to high affinity Rabbit polyclonal to OMG FcRI through the Fc-hinge areas [11]. IgG4S228P antibodies likely retain the binding to FcRI. Inside a syngeneic mouse model, an anti-PD-1 mAb NK314 with effector-less Fc region demonstrated superior anti-tumor efficacy as compared with the one with effector functions [14]. However, practical effects of FcRI engagement by anti-PD-1 mAb through IgG4S228P have not been well analyzed. FcRI is highly indicated in type 2 macrophages (M2) under inflammatory conditions in certain tumor NK314 types [15]. It is also indicated in myeloid-derived suppressor cells (MDSCs) and type I macrophages (M1). The functions induced by FcRI engagement span a wide scope of cellular activities including antibody-dependent cell phagocytosis (ADCP), cell proliferation, and production of cytokines depending on the cell type in which FcRI is definitely activated [16]. With this statement, we analyzed the functional effects of an anti-PD-1 mAb with an IgG4S228P weighty chain, for which we generated a pair of anti-PD-1 antibodies with the same variable areas, but with different forms of the IgG4 weighty chain: BGB-A317/IgG4S228P (with a single S228P mutation) and BGB-A317 (lack of FcR-binding capacity). Comparative characterization of these two mAbs shown that BGB-A317/IgG4S228P binds to human being FcRI with high affinity and mediates crosslinking between PD-1+ T cells and FcRI+ cells. In addition, the two BGB-A317 mAbs showed serious differences in their capacity to modulate T-cell and macrophage functions in vitro NK314 or inhibit tumor growth using xenograft model in vivo. Materials and methods Binding affinity assay by SPR For the characterization of the binding affinity of BGB-A317 or BGB-A317/IgG4S228P to human being PD-1, the extracellular website of the human being PD-1 protein, having a His tag (PD-1/His), was coupled to an triggered CM5 biosensor chip (Biacore?, GE Healthcare Life Sci). BGB-A317 or BGB-A317/IgG4S228P samples were injected and binding reactions to human being PD-1/His were determined by subtracting the response.
